Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Asahi Life Asset Management CO. LTD.

Asahi Life Asset Management CO. LTD. increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 23.4% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 845 shares of the biopharmaceutical company’s stock after purchasing an additional 160 shares during the period. Asahi Life Asset Management CO. LTD.’s holdings in Regeneron Pharmaceuticals were worth $444,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Nuveen LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $343,764,000. Pacer Advisors Inc. boosted its position in shares of Regeneron Pharmaceuticals by 2,296.9% in the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company’s stock valued at $258,366,000 after purchasing an additional 390,374 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Regeneron Pharmaceuticals by 18.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock valued at $724,984,000 after purchasing an additional 174,056 shares during the period. Vanguard Group Inc. boosted its position in shares of Regeneron Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock valued at $5,966,767,000 after purchasing an additional 121,545 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Regeneron Pharmaceuticals by 4.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock valued at $1,379,467,000 after purchasing an additional 89,579 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the sale, the director owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $644.19 on Thursday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $844.51. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.06. The stock’s 50 day moving average price is $585.15 and its 200 day moving average price is $566.94. The firm has a market cap of $68.28 billion, a P/E ratio of 15.43, a PEG ratio of 2.03 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. During the same quarter in the prior year, the company earned $12.46 EPS. Regeneron Pharmaceuticals’s revenue was up .9% on a year-over-year basis. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.43%.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of research analyst reports. Citigroup upped their target price on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Sanford C. Bernstein raised their price target on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a report on Wednesday, August 27th. Guggenheim raised their price target on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Bank of America raised their price target on Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the stock an “underperform” rating in a report on Wednesday, October 29th. Finally, Jefferies Financial Group raised their price target on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a report on Wednesday, August 27th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $792.95.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.